Your session is about to expire
← Back to Search
CAR T-Cell Therapy for Brain Cancer (iCAR Trial)
iCAR Trial Summary
This trial is for brain cancer patients specifically. It is testing a new way to fight cancer by combining two existing methods- antibodies and T cells. The purpose is to see if this new method is effective and has minimal side effects.
iCAR Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowiCAR Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.iCAR Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can care for myself but may need occasional help.My HER2 positive cancer has returned or didn’t respond to treatment and affects my brain.
- Group 1: HER2-specific T cells - High Risk
- Group 2: HER2-specific T cells - Standard Risk
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the usage of HER2-specific T cells officially sanctioned by the FDA?
"The safety of HER2-specific T cells was assessed at 1 due to its Phase 1 status, indicating limited evidence supporting safety and efficacy."
To what magnitude is the population involved in this research undertaking?
"Indeed. According to clinicaltrials.gov, this medical trial is presently recruiting and initially posted on February 1st 2016 with its most recent update being May 3rd 2022. It seeks 28 participants from 2 distinct locations."
Is there an opportunity for participants to join this clinical trial?
"Indeed, the information hosted on clinicaltrials.gov suggests that this medical research is actively recruiting patients; it was posted on February 1st 2016 and has undergone revisions as recently as May 3rd 2022. The team conducting the trial requires 28 participants to be enrolled from 2 different sites."
Share this study with friends
Copy Link
Messenger